Topical immunomodulators for treatment of eczema;Topische immunmodulatoren zur ekzembehandlung

Allergo Journal

Volumn 12, Issue 7, 2003, Pages 456-462

  Bornhövd, Elke ^a   Wollenberg, Andreas ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Atopic dermatitis; Pimecrolimus; Tacrolimus; TIM; Topical immunomodulators

Indexed keywords

ANTIINFLAMMATORY AGENT; CALCINEURIN; COLLAGEN; CYCLOSPORIN A; CYTOKINE; GLUCOCORTICOID; IMMUNOMODULATING AGENT; IMMUNOPHILIN; PIMECROLIMUS; PLACEBO; TACROLIMUS; TRANSCRIPTION FACTOR NFAT;

ATOPIC DERMATITIS; BASOPHIL; CLINICAL TRIAL; COLLAGEN SYNTHESIS; DENDRITIC CELL; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; ECZEMA; HUMAN; IMMUNOMODULATION; INFLAMMATORY CELL; KERATINOCYTE; LANGERHANS CELL; MAST CELL; REVIEW; SIDE EFFECT; SKIN INFLAMMATION; T LYMPHOCYTE;

EID: 0242642293     PISSN: 09418849     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03361262     Document Type: Review

References (67)

1. Abeck D, Strom K. Optimal management of atopic dermatitis. Am J Clin Dermatol 2000; 1: 41-6
2. Alaiti S, Kang S, Fiedler VC, Ellis CN, Spurlin DV, Fader D, Ulyanov G, Gadgil SD, Tanase A, Lawrence I, Scotellaro P, Raye K, Bekersky I. Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. J Am Acad Dermatol 1998; 38: 69-76
3. Allan R, Morris A, Cardno M, Scott G, Ebelin ME, Burtin P. Clinical experience with SDZ ASM 981 cream in children 5-16 years old with extensive atopic dermatitis. J Eur Acad Dermatol Venereol 1999; 12: S139-40
4. Arai T, Koyama Y, Suenaga T, Honda H. Ascomycin, an antifungal antibiotic. J Antibiot Ser A 1962; 15: 231-2
5. Beveca D, Schuler W, Schulz M, Werner F, Winiski A, Wolff B, Zenke G, Grassberger M. SDZ ASM 981 - a novel anti-inflammatory macrolactam: pharmacological activities in vitro. Aust J Dermatol 1997; 38: 285
6. Bieber T. Topical tacrolimus (FK 506): a new milestone in the management of atopic dermatitis. J Allergy Clin Immunol 1998; 102; 555-7
7. Boguniewicz M, Fiedler VC, Raimer S, Lawrence ID, Leung DY, Hanifin JM. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998; 102: 637-44
8. Bornhövd E, Burgdorf WHC, Wollenberg A. Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J Am Acad Dermatol 2001; 45: 736-43
9. Bornhövd EC, Burgdorf WHC, Wollenberg A. Immunomodulatory macrolactams for topical treatment of inflammatory skin diseases. Curr Opin Investig Drugs 2002; 3: 708-12
10. Bornhövd EC, Schuller E, Bieber T, Wollenberg A. Immunsuppressive Makrolide und ihr Einsatz in der Dermatologie. Hautarzt 2000; 51: 646-54
11. Choi CJ, Nghiem P. Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease: a case series of 18 patients. Arch Dermatol 2001; 137: 1202-6
12. Eberlein-König B, Michel G, Ruzicka T, Przybilla B. Modulation of histamine release in vitro by FK506 and interleukin-3 is determined by sequence of incubation. Arch Dermatol Res 1997; 289: 606-8
13. Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K, Bush C, Graeber M. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46: 495-504
14. FDA-webpage. http://www.fda.gov/cder/foi/nda/2001/21-302_Elidel.htm
15. Feldmann KA, Kunte C, Wollenberg A, Wolff H. Is topical tacrolimus effective in alopecia areata universalis? Br J Dermatol 2002; 147: 1031-2
16. Finlay AY. Quality of life in atopic dermatitis. J Am Acad Dermatol 2001; 45: S64-6
17. Fujisawa Healthcare I. Tacrolimus ointment (0.03% and 0.1%) in atopic dermatitis. Briefing document: NDA 50-777. Washington D. C.: Food and Drug Administration (FDA), 2000
18. Gieler U, Hohmann M, Niemeier V, Kupfer J, Stangier U, Ehlers A. Cost evaluation in atopic eczema. J Dermatol Treat 1999; 10: S15-25
19. Goto T, Kino T, Hatanaka H, Okuhara M, Kohsaka M, Aoki H, Imanaka H. FK 506: historical perspectives. Transplant Proc 1991; 23: 2713-7
20. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, Schuler W, Schulz M, Werner F, Winiski A, Wolff B, Zenke G. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999; 141: 264-73
21. Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002; 47: 789-91
22. Harper J, Green A, Ebelin ME, Scott G, Burtin P. Clinical experience with SDZ ASM 981 cream in children 1-4 years old with extensive atopic dermatitis. J Eur Acad Dermatol Venereol 1999; 12: S139
23. Herd RM, Tidman MJ, Prescott RJ, Hunter JA. The cost of atopic eczema. Br J Dermatol 1996; 135: 20-3
24. Kaliakatsou F, Hodgson TA, Lewsey JD, Hegarty AM, Murphy AG, Porter SR. Management of recalcitrant ulcerative oral lichen planus with topical tacrolimus. J Am Acad Dermatol 2002; 46: 35-41
25. Kang S, Lucky AW, Pariser D, Lawrence I, Hanifin JM. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44: S58-64
26. Kapp A, Papp K, Bingham A, Folster-Holst R, Ortonne JP, Potter PC, Gulliver W, Paul C, Molloy S, Barbier N, Thurston M, Prost Y de. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002; 110: 277-84
27. Kerschenlohr K, Schaller UC, Messmer EM, Wollenberg A. Das Lidekzem - eine therapeutische Herausforderung. Ophthalmologe 2003; 100: 240-51
28. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, Goto T, Okuhara M, Kohsaka M, Aoki H, Ochiai T. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 1987; 40: 1256-65
29. Krupnick A, Clarke J, Fadness D, Singer G, Lebwohl M. Tacrolimus 0.1% ointment in the treatment of eyelid dermatitis. J Invest Dermatol 2001; 117: 533
30. Lapidus CS, Schwarz DF, Honig PJ. Atopic dermatitis in children: who cares? Who pays? J Am Acad Dermatol 1993; 28: 699-703
31. Lauerma AI, Granlund H, Reitamo S. Use of the newer immunosuppressive agents in dermatology. BioDrugs 1997; 8: 96-106
32. Lauerma AI, Maibach HI, Granlund H, Erkko P, Kartamaa M, Stubb S. Inhibition of contact allergy reactions by topical FK506. Lancet 1992; 340: 556
33. Lener EV, Brieva J, Schachter M, West LE, West DP, el-Azhary RA. Successful treatment of erosive lichen planus with topical tacrolimus. Arch Dermatol 2001; 137: 419-22
34. Luger T, Van-Leent EJ, Graeber M, Hedgecock S, Thurston M, Kandra A, Berth-Jones J, Bjerke J, Christophers E, Knop J, Knulst AC, Morren M, Morris A, Reitamo S, Roed-Petersen J, Schöpf E, Thestrup-Pedersen K, Van-Der-Valk PG, Bos JD. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001; 144: 788-94
35. Marone G. Tacrolimus ointment for atopic dermatitis. N Engl J Med 1998; 393: 1788
36. Mayer K, Reinhard T, Reis A, Bohringer D, Sundmacher R. 0.1% FK 506-Salbe - eine neue therapeutische Option bei der atopischen Blepharitis. Klinische Studie an 14 Patienten. Klin Monatsbl Augenheilkd 2001; 218: 733-6
37. Meurer M, Fölster-Holst R, Wozel G, Weidinger G, Jünger M, Bräutigam M. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002; 205: 271-7
38. Mrowietz U, Graeber M, Bräutigam M, Thurston M, Wagenaar A, Weidinger G, Christophers E. The novel ascomycin derivate SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 1998; 139: 992-6
39. Panhans-Groß A, Novak N, Kraft S, Bieber T. Human epidermal Langerhans cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol 2001; 107: 345-52
40. Przybilla B, Eberlein-König B, Ruëff F. Practical management of atopic eczema. Lancet 1994; 343: 1342-6
41. Queille-Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G, Zagula M, Ortonne JP. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001; 144: 507-13
42. Reich K, Vente C, Neumann C. Topical tacrolimus for pyoderma gangrenosum. Br J Dermatol 1998; 139: 755-7
43. Reitamo S, Rissanen J, Remitz A, Granlund H, Erkko P, Elg P, Autio P, Lauerma AI, Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 1998; 111: 396-8
44. Reitamo S, Rustin M, Ruzicka T, Cambazard F, Kalimo K, Friedmann PS, Schöpf E, Lahfa M, Diepgen TL, Judodihardjo H, Wollenberg A, Berth-Jones J, Bieber T. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 547-55
45. Reitamo S, Van Leent EJ, Ho V, Harper J, Ruzicka T, Kalimo K, Cambazard F, Rustin M, Taieb A, Gratton D, Sauder D, Sharpe G, Smith C, Junger M, Prost Y de. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 539-46
46. Reitamo S, Wollenberg A, Schöpf E, Perrot JL, Marks R, Ruzicka T, Christophers E, Kapp A, Lahfa M, Rubins A, Jablonska S, Rustin M. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol 2000; 136: 999-1006
47. Remitz A, Kyllonen H, Granlund H, Reitamo S.Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol 2001; 107: 196-7
48. Remitz A, Reitamo S, Erkko P, Granlund H, Lauerma AI. Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol 1999; 141: 103-7
49. Ruzicka T, Assmann T, Homey B. Tacrolimus - the drug for the turn of the millennium? Arch Dermatol 1999; 135: 574-80
50. Ruzicka T, Bieber T, Schöpf E, Rubins A, Dobozy A, Bos J, Jablonska S, Ahmed I, Thestrup-Pedersen K, Daniel F, Finzi A, Reitamo S. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 1997; 337: 816-21
51. Sakuma S, Higashi Y, Sato N, Sasakawa T, Sengoku T, Ohkubo Y, Amaya T, Goto T. Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. Comparison with steroids. Int Immunopharmacol 2001; 1: 1219-26
52. Schäfer-Korting M, Schmid MH, Korting HC. Topical glucocorticoids with improved risk-benefit ratio. Rationale of a new concept. Drug Saf 1996; 14: 375-85
53. Schnopp C, Remling R, Möhrenschlager M, Weigl L, Ring J, Abeck D. Topical tacrolimus (FK506) and mometasone furoate in treatment of dyshidrotic palmar eczema: a randomized, observer-blinded trial. J Am Acad Dermatol 2002; 46: 73-7
54. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13: 136-42
55. Schulz BS, Michel G, Wagner S, Süss R, Beetz A, Peter RU, Kemeny L, Ruzicka T. Increased expression of epidermal IL-8 receptor in psoriasis. Down-regulation by FK-506 in vitro. J Immunol 1993; 151: 4399-406
56. Schuppe HC, Homey B, Assmann T, Martens R, Ruzicka T. Topical tacrolimus for pyoderma gangrenosum. Lancet 1998; 351: 832
57. Stockfleth E, Ulrich C, Meyer T, Christophers E. Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment. Recent Results Cancer Res 2002; 160: 251-8
58. Stütz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981) - preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 2001; 20: 233-41
59. Van Leent EJ, Graber M, Thurston M, Wagenaar A, Spuls PI, Bos JD. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998; 134: 805-9
60. Wollenberg A. The concept of immunomodulation in atopic dermatitis. Atopy Rep 2002; 2: 14-7
61. Wollenberg A, Bieber T. FK-506/Tacrolimus. In: Burg G, Dummer RG, eds. Strategies for Immunointerventions in Dermatology. Berlin: Springer-Verlag, 1997: 53-7
62. Wollenberg A, Bieber T. Atopic dermatitis: from the genes to skin lesions. Allergy 2000; 55: 205-13
63. Wollenberg A, Kraft S, Hanau D, Bieber T. Immunomorphological and ultrastructural characterization of Langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema. J Invest Dermatol 1996; 106: 446-53
64. Wollenberg A, Sharma S, von Bubnoff D, Geiger E, Haberstok J, Bieber T. Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol 2001; 107: 519-25
65. Yoshimasu T, Ohtani T, Sakamoto T, Oshima A, Furukawa F. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol 2002; 12: 50-2
66. Zonneveld IM, Rubins A, Jablonska S, Dobozy A, Ruzicka T, Kind P, Dubertret L, Bos JD. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol 1998; 134: 1101-2
67. Zuberbier T, Chong SU, Grunow K, Guhl S, Welker P, Grassberger M, Henz BM. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol 2001; 108: 275-80